Immunai
Immunai is an AI-native biotech that maps the human immune system via single-cell multiomics and the AMICA-OS platform, selling multi-year collaboration agreements to major pharmaceutical companies for target discovery, preclinical evaluation, and clinical trial optimization.
- Company typePrivate
- Founded2018
- HeadquartersNew York, United States
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Immunai does
Immunai is a New York-based AI-native biotechnology company founded in 2018 that maps and programs the human immune system using single-cell multiomics, machine learning, and proprietary software. Its core technology stack combines AMICA, the world's largest immune-focused harmonized single-cell database (5-6k studies, 800+ cell types, 500+ diseases, 300K+ patient samples), with the ImmunoDynamics Engine (IDE) for hypothesis generation and AMICA-OS, an AI operating system that integrates foundation AI models for biomarker discovery, patient stratification, and dose optimization. The platform delivers three solution modules: Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization.
The company sells through multi-year, custom-priced collaboration agreements with major biopharmaceutical firms, structured around upfront and milestone payments. Disclosed partners include AstraZeneca (three expanding agreements spanning oncology, immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications), Teva, Bristol Myers Squibb, and Boehringer Ingelheim, with academic collaborations supporting Mount Sinai, Weill Cornell Medicine, Harvard's MGH, and the Parker Institute. Announced deal potential across active collaborations exceeds $155M. The company also maintains offices in Israel, Switzerland, and the Czech Republic following the 2021 acquisitions of Nebion and Dropprint Genomics, and holds EU-U.S./Swiss-U.S. Data Privacy Framework certifications to support cross-border data processing.
Immunai has raised approximately $295M in total funding, including a $215M Series B in October 2021 at a valuation exceeding $1 billion, and operates with 101-250 employees under co-founder CEO Noam Solomon with scientific founders including Ansuman Satpathy, Danny Wells, and Dan Littman, plus former Pfizer CSO Mikael Dolsten on the board.
Immunai firmographics
Firmographics- Name
- Immunai
- Legal name
- Immunai Inc.
- Website
- https://immunai.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Immunai is an AI-native biotech that maps the human immune system via single-cell multiomics and the AMICA-OS platform, selling multi-year collaboration agreements to major pharmaceutical companies for target discovery, preclinical evaluation, and clinical trial optimization.
- Ownership category
- akta.pro rank
Immunai industry classification
Industry- Product category
- AI-driven single-cell multiomics platform for immune-related drug discovery
- NAICS
- Medical and Diagnostic Laboratories (6215)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Immunai is headquartered
LocationHeadquarters
- HQ city
- New York
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Immunai business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Pharmaceutical Partnership Agreements: Immunai generates revenue through multi-year collaboration agreements with pharmaceutical companies. These include upfront payments and potential milestone payments tied to research achievements, such as the AstraZeneca collaborations worth up to $18M, $85M (IBD), and $37.5M (oncology), plus the Boehringer Ingelheim agreement up to $15M and Bristol Myers Squibb partnership.
- Drug Discovery Services: Provides target discovery, preclinical evaluation, and clinical trial optimization services to pharmaceutical partners. The company supports decision-making along the drug discovery and development journey through its end-to-end platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Enterprise pharmaceutical collaborations with negotiated terms |
Go-to-market motion2 records
Distribution channels1 record
Marketing channels5 records
Immunai product offering
Product offeringCore offering
Immunai operates an AI-driven single-cell multiomics platform that maps the human immune system at single-cell resolution to support drug discovery and clinical development for pharmaceutical partners. Its offering combines the AMICA immune cell atlas database, the IDE AI analytical engine, and the AMICA-OS operating system to deliver target discovery, preclinical candidate evaluation, and clinical trial optimization services through multi-year enterprise collaboration agreements.
Product overview
Immunai offers a unified AI-driven platform combining the AMICA-OS AI operating system, the AMICA (Annotated Multiomic Immune Cell Atlas) database, and the ImmunoDynamics Engine (IDE). The platform leverages multi-omic, single-cell technologies and machine learning to map the immune system at unprecedented scale and resolution. Three integrated solution modules—Target Discovery, Preclinical Evaluation, and Clinical Trial Optimization—support pharmaceutical companies in making smarter choices, reducing risks, and accelerating progress in drug development.
Differentiator
Problem solved
Functional benefit
Brands
- AMICA-OS: AI operating system platform for immune system analysis and clinical decision support
- AMICA
Products and services
- AMICA (Annotated Multiomic Immune Cell Atlas) The world's largest immune-focused, harmonized single-cell database, serving as the data foundation for drug discovery and development. Comprises high-resolution single-cell data from public and proprietary clinical cohorts and experiments across tens of millions of cells, covering 5-6k studies, 800+ cell types, 500+ diseases, and 300K+ patient samples. Used by pharmaceutical R&D teams to augment experimental data and inform immune-related drug discovery.
- ImmunoDynamics Engine (IDE) AI analytical framework designed to enhance clinical decision-making by identifying and prioritizing immune activation features in relation to biological questions and desired clinical outcomes. Provides mechanistic insights for trial arm prioritization, patient stratification biomarkers, target identification, and preclinical efficacy evaluation for pharmaceutical partners.
- AMICA-OS AI operating system that combines large-scale clinical immunology data at single-cell resolution with advanced foundation AI models. Supports biomarker discovery, patient stratification, dose optimization, and treatment-response analysis in oncology and immunology clinical development. Used by major pharmaceutical companies including AstraZeneca, Teva, Bristol Myers Squibb, and Boehringer Ingelheim.
- Target Discovery Solution for identifying novel high-impact drug targets linked to disease using Immunai's multi-omic data generation and AI-powered analysis capabilities. Delivered to pharmaceutical partners as part of multi-year collaboration agreements to support immune-related target identification.
- Preclinical Evaluation Solution for prioritizing the most promising drug candidates for development using Immunai's computational pipelines and ML-driven hypothesis validation. Helps pharmaceutical partners de-risk candidates before committing to expensive clinical development.
- Clinical Trial Optimization Solution for better understanding drug mechanism of action, identifying the right patient groups, and determining optimal treatment strategies to maximize clinical trial success. Supports biomarker discovery, patient stratification, and dose optimization across oncology, immunology, and inflammation clinical programs.
Quantifiable outcome
- Reduced trial durations by up to 25%
- +2 more outcomes
Companies that use Immunai
Customer profileNamed customers4 records
Segments2 records
Ideal customer profiles2 records
Immunai technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
Immunai partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and flagship.
- Boehringer IngelheimcoreMulti-project collaboration valued at up to $15 million through 2027 to identify new therapeutic targets in cancer and autoimmune diseases. Combines Immunai's single-cell AI platform with Boehringer Ingelheim's drug discovery capabilities to analyze thousands of patient samples, focusing on T-cell dysfunction.
- AstraZenecaflagshipMulti-year AI-driven oncology collaboration, the third expansion of partnership. AstraZeneca leverages AMICA-OS platform for biomarker discovery, patient stratification, and dose optimization in clinical trials. Immunai eligible to receive up to $37.5M over 2026-2027. Collaboration began in late 2022, expanded from oncology into immunology, inflammation, cardiovascular inflammation, neuroinflammation, and metabolic indications.
- Bristol Myers SquibbcoreAI partnership to use AMICA-OS to improve clinical development through immune system insights. Aims to analyze high-dimensional immune data from clinical studies to support drug development.
- Mount SinaicoreGrand Collaboration Initiative for Single-Cell Immune Profiling. Selected researchers receive free single-cell RNA sequencing and multi-omic data for studies across autoimmune kidney disease, T-cell redirection therapy in multiple myeloma, neoadjuvant immunotherapy in NSCLC, and immunotherapy resistance in gastric cancer.
- Weill Cornell MedicinecoreGrand Collaboration Initiative for Single-Cell Immune Profiling academic partnership providing free single-cell RNA sequencing and multi-omic data to support cancer and immunology research.
- Massachusetts General Hospital (Harvard)coreGrand Collaboration Initiative for Single-Cell Immune Profiling academic partnership with Harvard Medical School-affiliated MGH.
- AstraZenecaflagship$85 million collaboration renewal to develop targeted IBD therapy using AI-driven immune system mapping and cell atlas technology to identify new drug targets.
- Parker InstitutecoreCollaboration to build one of the largest single-cell datasets in cancer. Partnership aims to advance cancer immunotherapy research through comprehensive single-cell immune profiling.
- TevacoreMulti-year AI collaboration to enhance clinical decision making in immuno-oncology clinical trials. Partnership includes vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody.
- AstraZenecaflagship$18 million initial collaboration for advanced clinical trial optimization using AI to improve cancer drug trials.
- Nebion AGcoreAcquisition of Swiss bioinformatics company Nebion to enhance target discovery and drug development capabilities. Involves integrating Nebion's data platform and curation team.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Immunai competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key highlights6 records
Customer concentration
Immunai social profiles
Digital presenceImmunai compliance and trust
Trust signalCompliance1 record
Immunai financial estimates
Financial estimateRevenue estimate
Valuation estimate
Immunai leadership team
Management profileNumber of profiles
Profiles10 records
Immunai subsidiaries and ownership
Company hierarchySubsidiaries1 record
Immunai funding detail
Funding detailFunding overview
Funding rounds3 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Immunai M&A and investment
M&A and investmentM&A2 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Immunai
What does Immunai do?
Immunai operates an AI-driven single-cell multiomics platform that maps the human immune system at single-cell resolution to support drug discovery and clinical development for pharmaceutical partners. Its offering combines the AMICA immune cell atlas database, the IDE AI analytical engine, and the AMICA-OS operating system to deliver target discovery, preclinical candidate evaluation, and clinical trial optimization services through multi-year enterprise collaboration agreements.
Is Immunai a public or private company?
Immunai is a private company. It is classified as venture growth investor backed and is currently operating.
When was Immunai founded?
Immunai was founded in 2018. It employs 101 to 250 people.
Where is Immunai based?
Immunai is headquartered in New York, United States, in the North America region.
How does Immunai make money?
Two revenue lines are on record. Pharmaceutical Partnership Agreements are the primary driver. The others are drug Discovery Services.
Does Immunai have an API?
No public API is recorded for Immunai.
What industry is Immunai in?
Immunai's product category is AI-driven single-cell multiomics platform for immune-related drug discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 6215 and its SIC code is 8071.